Venus Medtech (Hangzhou) Inc 2022 AR2

The report highlights Venus Medtech's progress in 2022, including the European commercial launch of its VenusP-Valve, the first self-expanding TPVR product approved under the CE MDR regulations. The company also completed the acquisition of Cardiovalve, expanding its structural heart disease portfolio into mitral and tricuspid valve treatments. Financially, Venus Medtech recorded revenue of RMB 406.5 million, though it experienced a net loss due to impairment provisions related to the Keystone Group. On the ESG front, the company established a three-tier ESG governance structure and achieved its 2022 environmental targets, including obtaining ISO 14001 and ISO 45001 certifications.

Company: Venus Medtech (Hangzhou) Inc

Sector: Health Care

Country: China

Year: 2022

Type: AR2

Pages: 309

Back to company

Venus Medtech (Hangzhou) Inc

Venus Medtech (Hangzhou) Inc 2022 Annual Report

Annual Report

The report highlights Venus Medtech's progress in 2022, including the European commercial launch of its VenusP-Valve, the first self-expanding TPVR product approved under the CE MDR regulations. The company also completed the acquisition of Cardiovalve, expanding its structural heart disease portfolio into mitral and tricuspid valve treatments. Financially, Venus Medtech recorded revenue of RMB 406.5 million, though it experienced a net loss due to impairment provisions related to the Keystone Group. On the ESG front, the company established a three-tier ESG governance structure and achieved its 2022 environmental targets, including obtaining ISO 14001 and ISO 45001 certifications.

Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.

Document Details

Report Year

2022

Reporting Period

Jan 1, 2022 - Dec 31, 2022

Fiscal Year

2022

Type

Annual Report with Sustainability Disclosures

Language

English

Pages

 

File Size

 

Standards & Assurance

Materiality Assessment

ESG Data?Experimental — AI-extracted data, may contain inaccuracies

Emissions

Scope 1:

Scope 2:

Energy Consumption

Water Consumption

Workplace Fatalities

Employees